SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin inches up on launching first generic version of Pred Forte in United States

15 Oct 2024 Evaluate

Lupin is currently trading at Rs. 2248.00, up by 4.85 points or 0.22% from its previous closing of Rs. 2243.15 on the BSE.

The scrip opened at Rs. 2234.15 and has touched a high and low of Rs. 2272.15 and Rs. 2234.15 respectively. So far 11302 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2312.00 on 05-Sep-2024 and a 52 week low of Rs. 1113.00 on 31-Oct-2023.

Last one week high and low of the scrip stood at Rs. 2311.65 and Rs. 2111.90 respectively. The current market cap of the company is Rs. 102488.56 crore.

The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 46.60% and 6.44% respectively.

Lupin has launched the first generic version of Pred Forte (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in the United States. Being the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy (CGT) exclusivity. 

Prednisolone Acetate Ophthalmic Suspension USP, 1% is a generic equivalent of Pred Forte Ophthalmic Suspension, 1% of AbbVie, Inc. and is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Pred Forte had estimated annual sales of $198 million in the U.S. (IQVIA MAT August 2024).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2442.35 98.95 (4.22%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×